BBIO
$67.25+0.51%
as of close, Oct 2, 2026
☾ AH $67.25 +0.51%
BridgeBio Pharma Inc.Stock · Health CareNasdaq Composite 0.03%US Stock Market 0.02%Russell 1000 0.02%Russell 3000 0.02%
BBIO SEC filings (2026)
CIK 1743881 · Pharmaceutical Preparations (SIC 2834) · incorporated in DE · fiscal year ends in December
826 filings on EDGAR since 2018 · 7 annual, 22 quarterly, 105 current · financial statements · earnings
Latest 10-K
Feb 24, 2026
fiscal year to Dec 31, 2025
Latest 10-Q
Aug 10, 2026
quarter to Jun 30, 2026
Latest 8-K
Aug 31, 2026
Other events
Last earnings release
Aug 10, 2026
−$0.78 vs −$0.64 · ▼ 1.1%
Filings on file
826
since 2018, 535 insider forms
What happened, last 12 months#
Every earnings release with its print, every report with its quarter, the other 8-Ks by what they covered, the proxy statements, and each day an insider bought or sold — newest first, each line opening the filing on EDGAR. The index by form and year follows.
September 2026
August 2026
- Aug 318-K8-K · Other events
- Aug 19Insider saleKumar Neil (Chief Executive Officer · Director) sold 10,000 shares for $840K at $83.86–$85.65 under a 10b5-1 plan
- Aug 18Insider saleKumar Neil (Chief Executive Officer · Director) sold 34,980 shares for $2.9M at $81.15–$83.77 under a 10b5-1 plan
- Aug 178-K8-K · Material definitive agreement; Other events
- Aug 10EarningsEarnings release — EPS −$0.78 vs −$0.64 est. (−21.9%); revenue $243.7M (+120% y/y) 1.1%
- Aug 10ReportQuarterly report, Q2 2026 — revenue $243.7M (+120% y/y), net income −$155.9M, EPS −$0.78
July 2026
- Jul 30Insider saleApuli Maricel (Chief Accounting Officer) sold 2,000 shares for $160K at $80.06 under a 10b5-1 plan
- Jul 228-K8-K · Other events
- Jul 9Insider saleCook Jennifer E. (Director) sold 148,589 shares for $13.2M at $84.00–$90.00 under a 10b5-1 plan
- Jul 9Insider saleEllis Andrea (Director) sold 17,167 shares for $1.4M at $84.00 under a 10b5-1 plan
- Jul 28-K8-K · Material definitive agreement; Unregistered sale of equity; Change to security holders' rights; Charter, bylaws or fiscal-year change; Regulation FD disclosure
June 2026
- Jun 268-K8-K · Directors or officers; compensation; Shareholder vote results
- Jun 24Insider saleCook Jennifer E. (Director) sold 37,167 shares for $2.6M at $70.00 under a 10b5-1 plan
- Jun 23Insider saleValantine Hannah (Director) sold 2,196 shares for $151K at $68.57 under a 10b5-1 plan
- Jun 23Insider saleCook Jennifer E. (Director) sold 2,196 shares for $151K at $68.57 under a 10b5-1 plan
- Jun 22Insider saleValantine Hannah (Director) sold 2,808 shares for $191K at $68.00 under a 10b5-1 plan
- Jun 15Insider saleCook Jennifer E. (Director) sold 90,240 shares for $6.0M at $66.62–$67.14 under a 10b5-1 plan
- Jun 5Insider saleKumar Neil (Chief Executive Officer · Director) sold 40,000 shares for $2.7M at $67.20–$68.96 under a 10b5-1 plan
- Jun 4Insider saleKumar Neil (Chief Executive Officer · Director) sold 40,000 shares for $2.7M at $65.72–$68.27 under a 10b5-1 plan
May 2026
- May 278-K8-K · Other events
- May 21Insider saleKumar Neil (Chief Executive Officer · Director) sold 26,103 shares for $1.8M at $67.57–$70.92 under a 10b5-1 plan
- May 18Insider saleTrimarchi Thomas (President and CFO) sold 13,651 shares for $888K at $64.82–$65.95 under a 10b5-1 plan
- May 15Insider saleScott Randal W. (Director) sold 10,000 shares for $671K at $66.69–$69.12 under a 10b5-1 plan
- May 138-K8-K · Other events
- May 8Insider saleKumar Neil (Chief Executive Officer · Director) sold 40,000 shares for $2.7M at $66.65–$68.35 under a 10b5-1 plan
- May 88-K8-K · Material definitive agreement; Termination of a material agreement
- May 7EarningsEarnings release — EPS −$0.84 vs −$0.70 est. (−20.0%); revenue $194.5M (+67% y/y) 0.1%
- May 7ReportQuarterly report, Q1 2026 — revenue $194.5M (+67% y/y), net income −$166.6M, EPS −$0.84
- May 7Insider saleKumar Neil (Chief Executive Officer · Director) sold 40,000 shares for $2.7M at $67.49–$69.09 under a 10b5-1 plan
April 2026
- Apr 30Insider saleApuli Maricel (Chief Accounting Officer) sold 2,000 shares for $143K at $71.58 under a 10b5-1 plan
- Apr 24ProxyProxy · Annual report to shareholders
- Apr 24ProxyProxy · Additional proxy materials
- Apr 24ProxyProxy · Proxy statement
- Apr 10Insider saleKumar Neil (Chief Executive Officer · Director) sold 40,000 shares for $3.0M at $74.60–$74.60 under a 10b5-1 plan
- Apr 9Insider saleKumar Neil (Chief Executive Officer · Director) sold 40,000 shares for $3.0M at $73.64–$75.55 under a 10b5-1 plan
March 2026
- Mar 308-K8-K · Other events
- Mar 13Insider saleKumar Neil (Chief Executive Officer · Director) sold 40,000 shares for $2.8M at $68.36–$69.23 under a 10b5-1 plan
- Mar 12Insider saleKumar Neil (Chief Executive Officer · Director) sold 40,000 shares for $2.7M at $68.47–$70.15 under a 10b5-1 plan
- Mar 10Insider saleValantine Hannah (Director) sold 8,671 shares for $624K at $72.00 under a 10b5-1 plan
- Mar 4Insider saleEllis Andrea (Director) sold 64,921 shares for $4.2M at $64.87 under a 10b5-1 plan
February 2026
- Feb 27Insider saleValantine Hannah (Director) sold 25,484 shares for $1.7M at $67.08–$67.84 under a 10b5-1 plan
- Feb 26Insider saleApuli Maricel (Chief Accounting Officer) sold 2,000 shares for $132K at $66.00 under a 10b5-1 plan
- Feb 24EarningsEarnings release — EPS −$1.00 vs −$0.75 est. (−33.3%); revenue $154.2M (+2521% y/y) 2.6%
- Feb 24ReportAnnual report, FY2025 — revenue $502.1M (+126% y/y), net income −$732.9M, EPS −$3.78
- Feb 19Insider saleKumar Neil (Chief Executive Officer · Director) sold 28,053 shares for $2.0M at $71.03–$72.80 under a 10b5-1 plan
- Feb 17Insider saleTrimarchi Thomas (President and CFO) sold 13,600 shares for $1.0M at $74.71–$75.38 under a 10b5-1 plan
- Feb 17Insider saleScott Randal W. (Director) sold 10,000 shares for $755K at $74.34–$75.93 under a 10b5-1 plan
- Feb 17Insider saleApuli Maricel (Chief Accounting Officer) sold 510 shares for $38K at $74.31 under a 10b5-1 plan
- Feb 128-K8-K · Other events
- Feb 11Insider saleKumar Neil (Chief Executive Officer · Director) sold 40,000 shares for $2.9M at $70.69–$73.25 under a 10b5-1 plan
- Feb 10Insider saleKumar Neil (Chief Executive Officer · Director) sold 40,000 shares for $2.9M at $71.80–$72.28 under a 10b5-1 plan
January 2026
- Jan 218-K8-K · Material definitive agreement; New financial obligation; Unregistered sale of equity; Other events
- Jan 128-K8-K · Results of operations; Regulation FD disclosure; Other events
- Jan 9Insider saleKumar Neil (Chief Executive Officer · Director) sold 40,000 shares for $3.1M at $75.61–$78.19 under a 10b5-1 plan
- Jan 8Insider saleKumar Neil (Chief Executive Officer · Director) sold 40,000 shares for $3.0M at $73.64–$75.20 under a 10b5-1 plan
October 2025
- Oct 29EarningsEarnings release — EPS −$0.95 vs −$0.88 est. (−8.0%); revenue $120.7M (+4318% y/y) 4.9%
- Oct 29ReportQuarterly report, Q3 2025 — revenue $120.7M (+4318% y/y), net income −$184.9M, EPS −$0.95
- Oct 298-K8-K · Other events
- Oct 278-K8-K · Other events
Insider transactions#
What officers, directors and 10% holders reported on Forms 4 and 5 over the last 13 months, from the documents themselves: one insider’s trades of one kind on one day are one row, with the shares, the price range and the total as filed. Open-market buys and sells first; awards, exercises, tax withholding, gifts and employee-plan purchases are grouped below them.
Over the last 13 months insiders sold $76.4M in 35 sales and bought nothing on the open market; 64 other transactions (awards, exercises, tax withholding, gifts and plan purchases).
| Date | Insider |
|---|---|
| Sep 17, 2026Form 4 | Kumar NeilChief Executive Officer · DirectorSold · $691K · 10,000 sh · 10b5-1 |
| Aug 19, 2026Form 4 | Kumar NeilChief Executive Officer · DirectorSold · $840K · 10,000 sh · 10b5-1 |
| Aug 18, 2026Form 4 | Kumar NeilChief Executive Officer · DirectorSold · $2.9M · 34,980 sh · 10b5-1 |
| Jul 30, 2026Form 4 | Apuli MaricelChief Accounting OfficerSold · $160K · 2,000 sh · 10b5-1 |
| Jul 9, 2026Form 4 | Cook Jennifer E.DirectorSold · $13.2M · 148,589 sh · 10b5-1 |
| Jul 9, 2026Form 4 | Ellis AndreaDirectorSold · $1.4M · 17,167 sh · 10b5-1 |
| Jun 24, 2026Form 4 | Cook Jennifer E.DirectorSold · $2.6M · 37,167 sh · 10b5-1 |
| Jun 23, 2026Form 4 | Valantine HannahDirectorSold · $151K · 2,196 sh · 10b5-1 |
| Jun 23, 2026Form 4 | Cook Jennifer E.DirectorSold · $151K · 2,196 sh · 10b5-1 |
| Jun 22, 2026Form 4 | Valantine HannahDirectorSold · $191K · 2,808 sh · 10b5-1 |
| Jun 15, 2026Form 4 | Cook Jennifer E.DirectorSold · $6.0M · 90,240 sh · 10b5-1 |
| Jun 5, 2026Form 4 | Kumar NeilChief Executive Officer · DirectorSold · $2.7M · 40,000 sh · 10b5-1 |
| Jun 4, 2026Form 4 | Kumar NeilChief Executive Officer · DirectorSold · $2.7M · 40,000 sh · 10b5-1 |
| May 21, 2026Form 4 | Kumar NeilChief Executive Officer · DirectorSold · $1.8M · 26,103 sh · 10b5-1 |
| May 18, 2026Form 4 | Trimarchi ThomasPresident and CFOSold · $888K · 13,651 sh · 10b5-1 |
| May 15, 2026Form 4 | Scott Randal W.DirectorSold · $671K · 10,000 sh · 10b5-1 |
| May 8, 2026Form 4 | Kumar NeilChief Executive Officer · DirectorSold · $2.7M · 40,000 sh · 10b5-1 |
| May 7, 2026Form 4 | Kumar NeilChief Executive Officer · DirectorSold · $2.7M · 40,000 sh · 10b5-1 |
| Apr 30, 2026Form 4 | Apuli MaricelChief Accounting OfficerSold · $143K · 2,000 sh · 10b5-1 |
| Apr 10, 2026Form 4 | Kumar NeilChief Executive Officer · DirectorSold · $3.0M · 40,000 sh · 10b5-1 |
| Apr 9, 2026Form 4 | Kumar NeilChief Executive Officer · DirectorSold · $3.0M · 40,000 sh · 10b5-1 |
| Mar 13, 2026Form 4 | Kumar NeilChief Executive Officer · DirectorSold · $2.8M · 40,000 sh · 10b5-1 |
| Mar 12, 2026Form 4 | Kumar NeilChief Executive Officer · DirectorSold · $2.7M · 40,000 sh · 10b5-1 |
| Mar 10, 2026Form 4 | Valantine HannahDirectorSold · $624K · 8,671 sh · 10b5-1 |
| Mar 4, 2026Form 4 | Ellis AndreaDirectorSold · $4.2M · 64,921 sh · 10b5-1 |
| Feb 27, 2026Form 4 | Valantine HannahDirectorSold · $1.7M · 25,484 sh · 10b5-1 |
| Feb 26, 2026Form 4 | Apuli MaricelChief Accounting OfficerSold · $132K · 2,000 sh · 10b5-1 |
| Feb 19, 2026Form 4 | Kumar NeilChief Executive Officer · DirectorSold · $2.0M · 28,053 sh · 10b5-1 |
| Feb 17, 2026Form 4 | Trimarchi ThomasPresident and CFOSold · $1.0M · 13,600 sh · 10b5-1 |
| Feb 17, 2026Form 4 | Scott Randal W.DirectorSold · $755K · 10,000 sh · 10b5-1 |
| Feb 17, 2026Form 4 | Apuli MaricelChief Accounting OfficerSold · $38K · 510 sh · 10b5-1 |
| Feb 11, 2026Form 4 | Kumar NeilChief Executive Officer · DirectorSold · $2.9M · 40,000 sh · 10b5-1 |
| Feb 10, 2026Form 4 | Kumar NeilChief Executive Officer · DirectorSold · $2.9M · 40,000 sh · 10b5-1 |
| Jan 9, 2026Form 4 | Kumar NeilChief Executive Officer · DirectorSold · $3.1M · 40,000 sh · 10b5-1 |
| Jan 8, 2026Form 4 | Kumar NeilChief Executive Officer · DirectorSold · $3.0M · 40,000 sh · 10b5-1 |
Awards, exercises, withholding and plan purchases · 64 transactions
| Date | Insider |
|---|---|
| Aug 16, 2026Form 4 | Kumar NeilChief Executive Officer · DirectorTax withholding · $2.9M · 36,237 sh |
| Aug 16, 2026Form 4 | Trimarchi ThomasPresident and CFOTax withholding · $1.8M · 22,781 sh |
| Aug 16, 2026Form 4 | Apuli MaricelChief Accounting OfficerTax withholding · $376K · 4,714 sh |
| Aug 16, 2026Form 4 | Kumar NeilChief Executive Officer · DirectorExercise or conversion · — · 71,217 sh |
| Aug 16, 2026Form 4 | Kumar NeilChief Executive Officer · DirectorExercise or conversion · Restricted Stock Units · $0 · 71,217 sh |
| Jul 9, 2026Form 4 | Cook Jennifer E.DirectorExercise or conversion · $3.7M · 148,589 sh · 10b5-1 |
| Jul 9, 2026Form 4 | Ellis AndreaDirectorExercise or conversion · $288K · 17,167 sh · 10b5-1 |
| Jul 9, 2026Form 4 | Cook Jennifer E.DirectorExercise or conversion · Stock Option (Right to Buy) · $0 · 148,589 sh · 10b5-1 |
| Jul 9, 2026Form 4 | Ellis AndreaDirectorExercise or conversion · Stock Option (right to buy) · $0 · 17,167 sh · 10b5-1 |
| Jun 24, 2026Form 4 | Cook Jennifer E.DirectorExercise or conversion · $457K · 37,167 sh · 10b5-1 |
| Jun 24, 2026Form 4 | Cook Jennifer E.DirectorExercise or conversion · Stock Option (Right to Buy) · $0 · 37,167 sh · 10b5-1 |
| Jun 22, 2026Form 4 | Valantine HannahDirectorExercise or conversion · $117K · 2,808 sh · 10b5-1 |
| Jun 22, 2026Form 4 | Satvat Ali J.DirectorAward · Stock Option (Right to Buy) · $0 · 5,277 sh |
| Jun 22, 2026Form 4 | Dachille Douglas A.DirectorAward · Stock Option (Right to Buy) · $0 · 5,277 sh |
| Jun 22, 2026Form 4 | MCCORMICK FRANKDirectorAward · Stock Option (Right to Buy) · $0 · 5,277 sh |
| Jun 22, 2026Form 4 | MOMTAZEE JAMES CDirectorAward · Stock Option (Right to Buy) · $0 · 5,277 sh |
| Jun 22, 2026Form 4 | Hassan FredDirectorAward · Stock Option (Right to Buy) · $0 · 5,277 sh |
| Jun 22, 2026Form 4 | Ellis AndreaDirectorAward · Stock Option (Right to Buy) · $0 · 5,277 sh |
| Jun 22, 2026Form 4 | DANIELS RONALD JDirectorAward · Stock Option (Right to Buy) · $0 · 5,277 sh |
| Jun 22, 2026Form 4 | AGUIAR ERICDirectorAward · Stock Option (Right to Buy) · $0 · 5,277 sh |
| Jun 22, 2026Form 4 | HOMCY CHARLES JDirectorAward · Stock Option (Right to Buy) · $0 · 5,277 sh |
| Jun 22, 2026Form 4 | Lo AndrewDirectorAward · Stock Option (Right to Buy) · $0 · 5,277 sh |
| Jun 22, 2026Form 4 | Valantine HannahDirectorAward · Stock Option (Right to Buy) · $0 · 5,277 sh · 10b5-1 |
| Jun 22, 2026Form 4 | Cook Jennifer E.DirectorAward · Stock Option (Right to Buy) · $0 · 5,277 sh · 10b5-1 |
| Jun 22, 2026Form 4 | Satvat Ali J.DirectorAward · $0 · 3,990 sh |
| Jun 22, 2026Form 4 | Dachille Douglas A.DirectorAward · $0 · 3,990 sh |
| Jun 22, 2026Form 4 | MCCORMICK FRANKDirectorAward · $0 · 3,990 sh |
| Jun 22, 2026Form 4 | MOMTAZEE JAMES CDirectorAward · $0 · 3,990 sh |
| Jun 22, 2026Form 4 | Hassan FredDirectorAward · $0 · 3,990 sh |
| Jun 22, 2026Form 4 | Ellis AndreaDirectorAward · $0 · 3,990 sh |
| Jun 22, 2026Form 4 | DANIELS RONALD JDirectorAward · $0 · 3,990 sh |
| Jun 22, 2026Form 4 | AGUIAR ERICDirectorAward · $0 · 3,990 sh |
| Jun 22, 2026Form 4 | HOMCY CHARLES JDirectorAward · $0 · 3,990 sh |
| Jun 22, 2026Form 4 | Lo AndrewDirectorAward · $0 · 3,990 sh |
| Jun 22, 2026Form 4 | Valantine HannahDirectorAward · $0 · 3,990 sh · 10b5-1 |
| Jun 22, 2026Form 4 | Cook Jennifer E.DirectorAward · $0 · 3,990 sh · 10b5-1 |
| Jun 22, 2026Form 4 | Valantine HannahDirectorExercise or conversion · Stock Option (Right to Buy) · $0 · 2,808 sh · 10b5-1 |
| Jun 20, 2026Form 4 | HOMCY CHARLES JDirectorTax withholding · $52K · 788 sh |
| Jun 15, 2026Form 4 | Cook Jennifer E.DirectorExercise or conversion · $845K · 83,088 sh · 10b5-1 |
| Jun 15, 2026Form 4 | Cook Jennifer E.DirectorExercise or conversion · Stock Option (Right to Buy) · $0 · 83,088 sh · 10b5-1 |
| May 16, 2026Form 4 | Kumar NeilChief Executive Officer · DirectorTax withholding · $2.4M · 36,236 sh |
| May 16, 2026Form 4 | Trimarchi ThomasPresident and CFOTax withholding · $1.5M · 22,781 sh · 10b5-1 |
| May 16, 2026Form 4 | Apuli MaricelChief Accounting OfficerTax withholding · $312K · 4,714 sh |
| May 16, 2026Form 4 | Kumar NeilChief Executive Officer · DirectorExercise or conversion · — · 71,215 sh |
| May 16, 2026Form 4 | Kumar NeilChief Executive Officer · DirectorExercise or conversion · Restricted Stock Units · $0 · 71,215 sh |
| May 15, 2026Form 4 | Scott Randal W.DirectorExercise or conversion · $168K · 10,000 sh · 10b5-1 |
| May 15, 2026Form 4 | Scott Randal W.DirectorExercise or conversion · Stock Option (Right to Buy) · $0 · 10,000 sh · 10b5-1 |
| Mar 18, 2026Form 4 | Trimarchi ThomasPresident and CFOAward · $0 · 59,041 sh |
| Mar 18, 2026Form 4 | Apuli MaricelChief Accounting OfficerAward · $0 · 14,170 sh |
| Mar 17, 2026Form 4 | Kumar NeilChief Executive Officer · DirectorAward · Restricted Stock Units · $0 · 104,313 sh |
| Mar 17, 2026Form 4 | Kumar NeilChief Executive Officer · DirectorAward · Stock Option (Right to Buy) · $0 · 40,570 sh |
| Mar 10, 2026Form 4 | Valantine HannahDirectorExercise or conversion · $237K · 8,671 sh · 10b5-1 |
| Mar 10, 2026Form 4 | Valantine HannahDirectorExercise or conversion · Stock Option (Right to Buy) · $0 · 8,671 sh · 10b5-1 |
| Mar 4, 2026Form 4 | Ellis AndreaDirectorExercise or conversion · $549K · 64,921 sh · 10b5-1 |
| Mar 4, 2026Form 4 | Ellis AndreaDirectorExercise or conversion · Stock Option (right to buy) · $0 · 64,921 sh · 10b5-1 |
| Feb 27, 2026Form 4 | Valantine HannahDirectorExercise or conversion · $1.2M · 25,484 sh · 10b5-1 |
| Feb 27, 2026Form 4 | Valantine HannahDirectorExercise or conversion · Stock Option (Right to Buy) · $0 · 25,484 sh · 10b5-1 |
| Feb 17, 2026Form 4 | Scott Randal W.DirectorExercise or conversion · $168K · 10,000 sh · 10b5-1 |
| Feb 17, 2026Form 4 | Scott Randal W.DirectorExercise or conversion · Stock Option (Right to Buy) · $0 · 10,000 sh · 10b5-1 |
| Feb 16, 2026Form 4 | Kumar NeilChief Executive Officer · DirectorTax withholding · $2.3M · 30,970 sh |
| Feb 16, 2026Form 4 | Trimarchi ThomasPresident and CFOTax withholding · $1.4M · 18,819 sh · 10b5-1 |
| Feb 16, 2026Form 4 | Apuli MaricelChief Accounting OfficerTax withholding · $327K · 4,349 sh · 10b5-1 |
| Feb 16, 2026Form 4 | Kumar NeilChief Executive Officer · DirectorExercise or conversion · — · 64,698 sh |
| Feb 16, 2026Form 4 | Kumar NeilChief Executive Officer · DirectorExercise or conversion · Restricted Stock Units · $0 · 64,698 sh |
Reports and proxy statements#
Annual reports (10-K, 20-F, 40-F), quarterly reports (10-Q), current reports (8-K, 6-K) and proxy statements, newest first. An 8-K is described by its items. A form opens the document on EDGAR, or the filing’s index where it furnishes exhibits (an earnings release is the 8-K’s Exhibit 99.1).
2026 · 21 filings
| Filed | What it is |
|---|---|
| Aug 31, 20268-K | Other events |
| Aug 17, 20268-K | Material definitive agreement; Other events |
| Aug 10, 202610-Q | Quarterly report, Q2 2026 — revenue $243.7M (+120% y/y), net income −$155.9M, EPS −$0.78 |
| Aug 10, 20268-K | Earnings release — EPS −$0.78 vs −$0.64 est. (−21.9%); revenue $243.7M (+120% y/y) 1.1% |
| Jul 22, 20268-K | Other events |
| Jul 2, 20268-K | Material definitive agreement; Unregistered sale of equity; Change to security holders' rights; Charter, bylaws or fiscal-year change; Regulation FD disclosure |
| Jun 26, 20268-K | Directors or officers; compensation; Shareholder vote results |
| May 27, 20268-K | Other events |
| May 13, 20268-K | Other events |
| May 8, 20268-K | Material definitive agreement; Termination of a material agreement |
| May 7, 202610-Q | Quarterly report, Q1 2026 — revenue $194.5M (+67% y/y), net income −$166.6M, EPS −$0.84 |
| May 7, 20268-K | Earnings release — EPS −$0.84 vs −$0.70 est. (−20.0%); revenue $194.5M (+67% y/y) 0.1% |
| Apr 24, 2026ARS | Annual report to shareholders |
| Apr 24, 2026DEFA14A | Additional proxy materials |
| Apr 24, 2026DEF 14A | Proxy statement |
| Mar 30, 20268-K | Other events |
| Feb 24, 202610-K | Annual report, FY2025 — revenue $502.1M (+126% y/y), net income −$732.9M, EPS −$3.78 |
| Feb 24, 20268-K | Earnings release — EPS −$1.00 vs −$0.75 est. (−33.3%); revenue $154.2M (+2521% y/y) 2.6% |
| Feb 12, 20268-K | Other events |
| Jan 21, 20268-K | Material definitive agreement; New financial obligation; Unregistered sale of equity; Other events |
| Jan 12, 20268-K | Results of operations; Regulation FD disclosure; Other events |
2025 · 20 filings
| Filed | What it is |
|---|---|
| Oct 29, 202510-Q | Quarterly report, Q3 2025 — revenue $120.7M (+4318% y/y), net income −$184.9M, EPS −$0.95 |
| Oct 29, 20258-K | Other events |
| Oct 29, 20258-K | Earnings release — EPS −$0.95 vs −$0.88 est. (−8.0%); revenue $120.7M (+4318% y/y) 4.9% |
| Oct 27, 20258-K | Other events |
| Aug 5, 202510-Q | Quarterly report, Q2 2025 — revenue $110.6M (+5000% y/y), net income −$183.8M, EPS −$0.95 |
| Aug 5, 20258-K | Results of operations |
| Jul 2, 20258-K | Material definitive agreement; New financial obligation |
| Jun 23, 20258-K | Change to security holders' rights; Charter, bylaws or fiscal-year change; Shareholder vote results |
| May 9, 2025DEFA14A | Additional proxy materials |
| Apr 30, 2025DEFA14A | Additional proxy materials |
| Apr 30, 2025ARS | Annual report to shareholders |
| Apr 30, 2025DEF 14A | Proxy statement |
| Apr 29, 202510-Q | Quarterly report, Q1 2025 — revenue $116.6M (−45% y/y), net income −$169.6M, EPS −$0.88 |
| Apr 29, 20258-K | Results of operations |
| Apr 16, 2025PRE 14A | Preliminary proxy statement |
| Mar 17, 20258-K | Directors or officers; compensation; Regulation FD disclosure |
| Feb 28, 20258-K | Material definitive agreement; Termination of a material agreement; New financial obligation; Unregistered sale of equity; Other events |
| Feb 20, 202510-K | Annual report, FY2024 — revenue $221.9M (+2285% y/y), net income −$543.3M, EPS −$2.88 |
| Feb 20, 20258-K | Results of operations |
| Jan 13, 20258-K | Results of operations; Regulation FD disclosure; Other events |
2024 · 21 filings
| Filed | What it is |
|---|---|
| Nov 25, 20248-K | Other events |
| Nov 12, 202410-Q | Quarterly report, Q3 2024 — revenue $2.7M (−33% y/y), net income −$164.3M, EPS −$0.86 |
| Nov 12, 20248-K | Results of operations |
| Sep 11, 20248-K | Other events |
| Aug 21, 20248-K | Material definitive agreement |
| Aug 1, 202410-Q | Quarterly report, Q2 2024 — revenue $2.2M (+32% y/y), net income −$75.5M, EPS −$0.39 |
| Aug 1, 20248-K | Results of operations |
| Jul 23, 20248-K | Directors or officers; compensation; Regulation FD disclosure |
| Jun 24, 20248-K | Shareholder vote results |
| Jun 6, 20248-K | Other events |
| May 2, 202410-Q | Quarterly report, Q1 2024 — revenue $211.1M (+11462% y/y), net income −$36.2M, EPS −$0.20 |
| May 2, 20248-K | Results of operations |
| Apr 25, 2024ARS | Annual report to shareholders |
| Apr 25, 2024DEFA14A | Additional proxy materials |
| Apr 25, 2024DEF 14A | Proxy statement |
| Mar 6, 20248-K | Material definitive agreement; Other events |
| Mar 4, 20248-K | Material definitive agreement |
| Feb 22, 202410-K | Annual report, FY2023 — revenue $9.3M (−88% y/y), net income −$653.3M, EPS −$3.95 |
| Feb 22, 20248-K | Results of operations |
| Jan 18, 20248-K | Material definitive agreement; Termination of a material agreement; New financial obligation |
| Jan 8, 20248-K | Other events |
2023 · 17 filings — 10 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms
| Filed | What it is |
|---|---|
| Nov 2, 202310-Q | Quarterly report, Q3 2023 — revenue $4.1M (+1110% y/y), net income −$179.5M, EPS −$1.08 |
| Aug 3, 202310-Q | Quarterly report, Q2 2023 — revenue $1.6M (−98% y/y), net income −$160.7M, EPS −$0.98 |
| May 4, 202310-Q | Quarterly report, Q1 2023 — revenue $1.8M (+8% y/y), net income −$142.7M, EPS −$0.92 |
| Apr 28, 2023ARS | Annual report to shareholders |
| Apr 28, 2023DEFA14A | Additional proxy materials |
| Apr 28, 2023DEF 14A | Proxy statement |
| Feb 23, 202310-K | Annual report, FY2022 — revenue $77.6M (+11% y/y), net income −$484.7M, EPS −$3.26 |
10 current reports (8-K) not listed; the year is on EDGAR.
2022 · 16 filings — 10 × 8-K, 3 × 10-Q, 1 × 10-K and 2 other forms
| Filed | What it is |
|---|---|
| Nov 3, 202210-Q | Quarterly report, Q3 2022 — revenue $338K (−86% y/y), net income −$140.2M, EPS −$0.93 |
| Aug 4, 202210-Q | Quarterly report, Q2 2022 — revenue $73.7M (+37% y/y), net income −$2.6M, EPS −$0.07 |
| May 5, 202210-Q | Quarterly report, Q1 2022 — revenue $1.7M (+267% y/y), net income −$201.3M, EPS −$1.35 |
| Apr 29, 2022DEFA14A | Additional proxy materials |
| Apr 29, 2022DEF 14A | Proxy statement |
| Feb 25, 202210-K | Annual report, FY2021 — revenue $69.7M (+745% y/y), net income −$586.5M, EPS −$3.90 |
10 current reports (8-K) not listed; the year is on EDGAR.
2021 · 28 filings — 21 × 8-K, 3 × 10-Q, 2 × DEF 14A and 2 other forms
| Filed | What it is |
|---|---|
| Nov 8, 2021DEF 14A | Proxy statement |
| Nov 4, 202110-Q | Quarterly report, Q3 2021 — revenue $2.3M (−71% y/y), net income −$161.0M, EPS −$1.06 |
| Oct 29, 2021PRE 14A | Preliminary proxy statement |
| Aug 5, 202110-Q | Quarterly report, Q2 2021 — revenue $54.0M, net income −$102.1M, EPS −$0.66 |
| May 6, 202110-Q | Quarterly report, Q1 2021 — revenue $462K, net income −$171.1M |
| Apr 30, 2021DEF 14A | Proxy statement |
| Feb 25, 202110-K | Annual report, FY2020 — revenue $8.2M (−80% y/y), net income −$505.5M, EPS −$3.80 |
21 current reports (8-K) not listed; the year is on EDGAR.
2020 · 25 filings — 18 × 8-K, 3 × 10-Q, 1 × 10-K and 3 other forms
| Filed | What it is |
|---|---|
| Dec 15, 2020DEFM14A | Merger proxy statement |
| Nov 5, 202010-Q | Quarterly report, Q3 2020 — revenue $8.1M (−70% y/y), net income −$130.2M |
| Aug 11, 202010-Q | Quarterly report, Q2 2020 — net income −$136.2M |
| May 14, 202010-Q | Quarterly report, Q1 2020 — net income −$104.1M |
| Apr 23, 2020DEFA14A | Additional proxy materials |
| Apr 22, 2020DEF 14A | Proxy statement |
| Mar 3, 202010-K | Annual report, FY2019 — revenue $40.6M, net income −$288.6M |
18 current reports (8-K) not listed; the year is on EDGAR.
Insider, ownership and other filings#
Insider ownership (Forms 3, 4, 5 and 144), beneficial ownership (Schedules 13D and 13G), registration and prospectus (S-1, S-3, S-8, 424B and related) and the rest, counted by year, with the newest 25 of each of the latest 3 years shown. A Form 4 is one insider’s transaction report; a 13G is a passive holder above five percent.
2026 · 83 filings — 46 × 4, 23 × 144, 4 × SCHEDULE 13D/A and 5 other forms
| Filed | What it is |
|---|---|
| Sep 21, 20264 | Insider transaction (Form 4) |
| Aug 20, 20264 | Insider transaction (Form 4) |
| Aug 19, 2026144 | Notice of proposed sale (Form 144) |
| Aug 18, 20264 | Insider transaction (Form 4) |
| Aug 18, 20264 | Insider transaction (Form 4) |
| Aug 18, 20264 | Insider transaction (Form 4) |
| Aug 18, 2026144 | Notice of proposed sale (Form 144) |
| Aug 17, 2026SCHEDULE 13D/A | Other filings |
| Aug 17, 2026144 | Notice of proposed sale (Form 144) |
| Aug 14, 2026424B7 | Registration and prospectus |
| Aug 3, 20264 | Insider transaction (Form 4) |
| Aug 3, 2026SCHEDULE 13G/A | Other filings |
| Jul 24, 2026S-3ASR | Automatic shelf registration |
| Jul 24, 2026S-8 | Employee stock plan registration |
| Jul 13, 20264 | Insider transaction (Form 4) |
| Jul 13, 20264 | Insider transaction (Form 4) |
| Jul 10, 2026SCHEDULE 13D/A | Other filings |
| Jul 9, 2026144 | Notice of proposed sale (Form 144) |
| Jul 9, 2026144 | Notice of proposed sale (Form 144) |
| Jun 24, 20264 | Insider transaction (Form 4) |
| Jun 24, 20264 | Insider transaction (Form 4) |
| Jun 24, 20264 | Insider transaction (Form 4) |
| Jun 24, 20264 | Insider transaction (Form 4) |
| Jun 24, 20264 | Insider transaction (Form 4) |
| Jun 24, 20264 | Insider transaction (Form 4) |
The newest 25 of 83 shown; the full year is on EDGAR.
2025 · 129 filings — 72 × 4, 41 × 144, 7 × SCHEDULE 13D/A and 5 other forms
| Filed | What it is |
|---|---|
| Dec 16, 20254 | Insider transaction (Form 4) |
| Dec 16, 20254 | Insider transaction (Form 4) |
| Dec 16, 20254 | Insider transaction (Form 4) |
| Dec 15, 2025144 | Notice of proposed sale (Form 144) |
| Dec 10, 20254 | Insider transaction (Form 4) |
| Dec 8, 20254 | Insider transaction (Form 4) |
| Nov 24, 20254 | Insider transaction (Form 4) |
| Nov 20, 2025144 | Notice of proposed sale (Form 144) |
| Nov 19, 20254 | Insider transaction (Form 4) |
| Nov 19, 20254 | Insider transaction (Form 4) |
| Nov 18, 20254 | Insider transaction (Form 4) |
| Nov 18, 20254 | Insider transaction (Form 4) |
| Nov 18, 20254 | Insider transaction (Form 4) |
| Nov 18, 2025144 | Notice of proposed sale (Form 144) |
| Nov 17, 2025144 | Notice of proposed sale (Form 144) |
| Nov 17, 2025144 | Notice of proposed sale (Form 144) |
| Nov 17, 2025144 | Notice of proposed sale (Form 144) |
| Nov 14, 2025SCHEDULE 13D/A | Other filings |
| Nov 14, 20254 | Insider transaction (Form 4) |
| Nov 14, 2025SCHEDULE 13G | Other filings |
| Nov 12, 2025144 | Notice of proposed sale (Form 144) |
| Nov 10, 20254 | Insider transaction (Form 4) |
| Nov 7, 20254 | Insider transaction (Form 4) |
| Nov 6, 2025144 | Notice of proposed sale (Form 144) |
| Oct 31, 20254 | Insider transaction (Form 4) |
The newest 25 of 129 shown; the full year is on EDGAR.
2024 · 64 filings — 41 × 4, 8 × 144, 6 × SC 13G/A and 5 other forms
| Filed | What it is |
|---|---|
| Dec 31, 20244 | Insider transaction (Form 4) |
| Dec 27, 20244 | Insider transaction (Form 4) |
| Dec 27, 20244 | Insider transaction (Form 4) |
| Dec 12, 20244 | Insider transaction (Form 4) |
| Dec 12, 20244 | Insider transaction (Form 4) |
| Dec 12, 20244 | Insider transaction (Form 4) |
| Nov 20, 20244 | Insider transaction (Form 4) |
| Nov 20, 20244 | Insider transaction (Form 4) |
| Nov 19, 20244 | Insider transaction (Form 4) |
| Nov 19, 20244 | Insider transaction (Form 4) |
| Nov 19, 20244 | Insider transaction (Form 4) |
| Nov 19, 2024144 | Notice of proposed sale (Form 144) |
| Nov 19, 2024144 | Notice of proposed sale (Form 144) |
| Nov 12, 2024SC 13G/A | Passive holder above 5% (Schedule 13G), amended |
| Nov 6, 2024SC 13D/A | Active holder above 5% (Schedule 13D), amended |
| Oct 22, 2024SC 13G/A | Passive holder above 5% (Schedule 13G), amended |
| Sep 17, 20244 | Insider transaction (Form 4) |
| Sep 17, 2024SC 13D/A | Active holder above 5% (Schedule 13D), amended |
| Sep 13, 2024144 | Notice of proposed sale (Form 144) |
| Aug 20, 2024SC 13D/A | Active holder above 5% (Schedule 13D), amended |
| Aug 20, 20244 | Insider transaction (Form 4) |
| Aug 20, 20244 | Insider transaction (Form 4) |
| Aug 20, 20244 | Insider transaction (Form 4) |
| Aug 19, 2024144 | Notice of proposed sale (Form 144) |
| Aug 19, 2024144 | Notice of proposed sale (Form 144) |
The newest 25 of 64 shown; the full year is on EDGAR.
2023 · 76 filings — 46 × 4, 15 × 144, 3 × S-3ASR and 7 other forms
Counted, not listed; the year is on EDGAR.
2022 · 46 filings — 41 × 4, 4 × SC 13G/A, 1 × S-8
Counted, not listed; the year is on EDGAR.
2021 · 54 filings — 35 × 4, 4 × 3, 3 × 425 and 6 other forms
Counted, not listed; the year is on EDGAR.
2020 · 130 filings — 100 × 4, 5 × 3, 3 × 425 and 15 other forms
Counted, not listed; the year is on EDGAR.
2019 · 77 filings — 24 × 4, 16 × 3, 6 × CORRESP and 16 other forms
Counted, not listed; the year is on EDGAR.
2018 · 11 filings — 4 × 4, 3 × SC 13D/A, 2 × 4/A and 2 other forms
Counted, not listed; the year is on EDGAR.
About this data
BridgeBio Pharma Inc. (BBIO) has 826 filings on EDGAR going back to 2018: 7 annual reports, 22 quarterly reports and 105 current reports, plus proxy statements, insider forms and ownership schedules. Its latest annual report, a 10-K, was filed on Feb 24, 2026 for the fiscal year ended Dec 31, 2025. The most recent 8-K, on Aug 31, 2026, covered other events. Over the last 13 months insiders sold $76.4M in 35 sales and bought nothing on the open market; 64 other transactions (awards, exercises, tax withholding, gifts and plan purchases). Not investment advice.
Every row is a filing EDGAR lists for the registrants that have been BridgeBio Pharma Inc., read from the SEC’s submissions index each morning; a filing accepted after that read appears the next day. Where a company changed its filing entity (a holding-company reorganisation, Google into Alphabet) the predecessor’s filings are shown for the years it filed as the company, derived from the filings themselves. Dates are the filing date; the period is the report’s own. The latest 3 years of reports are listed in full, the next years to 10 without their 8-Ks, and older years are counted; the other forms are counted too, with the newest 25 of each of the latest 3 years shown. Insider transactions are the Form 4 and Form 5 documents themselves, filed since January 2026, every number as the insider filed it: a day’s lots are summed, a blank price adds its shares and no dollars, and a purchase through an employee stock plan is a plan purchase, not insider buying. The documents stay on sec.gov, public domain, and every link opens the SEC’s copy. ChartRow does not summarise or interpret filings.
FAQ#
- Where can I read BBIO's latest 10-K?
- BBIO's latest annual report, a 10-K, was filed on Feb 24, 2026 for the fiscal year ended Dec 31, 2025. It is linked above and opens on EDGAR, the SEC's own site, where every exhibit is also listed.
- When did BBIO last file an 8-K?
- On Aug 31, 2026: other events. An 8-K reports a material event between quarterly reports; the one that furnishes the quarter's results is filed under Item 2.02, last on Aug 10, 2026.
- Are BBIO insiders buying or selling?
- Over the last 13 months insiders sold $76.4M in 35 sales and bought nothing on the open market; 64 other transactions (awards, exercises, tax withholding, gifts and plan purchases). The most recent sale: Kumar Neil (Chief Executive Officer · Director) sold 10,000 shares on Sep 17, 2026 for $691K, under a 10b5-1 plan. Every figure is as the insider filed it on Form 4; a sale under a 10b5-1 plan was scheduled in advance.
- How many SEC filings has BBIO made?
- 826 filings are on EDGAR under the registrant records that have been BridgeBio Pharma Inc., going back to 2018; 535 of them are insider ownership forms (Forms 3, 4, 5 and 144).